Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shire Human Genetic Therapies, Inc.
ClinicalTrials.gov Identifier:
NCT01614574
First received: June 6, 2012
Last updated: May 31, 2013
Last verified: May 2013
  Purpose

Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB) that leads to progressive accumulation of glucocerebroside within macrophages and subsequent tissue and organ damage; typically of the liver, spleen, bone marrow, and brain. The disease has been classified into 3 clinical subtypes based on the presence or absence of neurological symptoms and severity of neurological disease. Type 1 Gaucher disease affects an estimated 30,000 persons worldwide and is the most common. Type 1 Gaucher disease does not involve the central nervous system. Patients with type 2 Gaucher disease present with acute neurological deterioration, which leads to early death. Those with type 3 disease typically display a more sub-acute neurological course, with later onset and slower progression.

The primary objective of this study is to evaluate the safety of every other week dosing of velaglucerase alfa in Japanese patients with Gaucher disease.

Velaglucerase alfa has been developed and approved as an enzyme replacement therapy for Type 1 Gaucher disease.


Condition Intervention Phase
Gaucher Disease
Biological: velaglucerase alfa
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease

Resource links provided by NLM:


Further study details as provided by Shire Human Genetic Therapies, Inc.:

Primary Outcome Measures:
  • Safety [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    • Proportion of patients with at least one study drug-related adverse events
    • Proportion of patients with at least one infusion-related adverse events
    • Proportion of patients with at least one serious adverse events
    • Proportion of patients with at least one concomitant medication
    • Proportion of patients with clinically abnormal laboratory tests
    • Proportion of patients with a positive anti-velaglucerase alfa antibody test


Secondary Outcome Measures:
  • Change from Baseline in hemoglobin concentration [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    g/dL

  • Change from Baseline in platelet count [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    x10e9/L

  • Change from Baseline in liver volume by abdominal magnetic resonance imaging (MRI) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    % body weight

  • Change from Baseline in spleen volume by MRI [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    % body weight


Enrollment: 6
Study Start Date: March 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Investigational
velaglucerase alfa
Biological: velaglucerase alfa
60 U/kg every other week intravenous infusion
Other Names:
  • VPRIV
  • Gene activated human glucocerebrosidase

Detailed Description:

Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB) that leads to progressive accumulation of glucocerebroside within macrophages and subsequent tissue and organ damage; typically of the liver, spleen, bone marrow, and brain.

Gaucher disease has been designated in the list of Specified Rare and Intractable Diseases by Specified Disease Treatment Research Program of Ministry of Health, Labor and Welfare (MHLW) as one of "lysosomal storage diseases" since 2001. Gaucher disease is also designated in the Medical Aid Program for Specified Categories of Chronic Pediatric Diseases.

The prevalence of mutations and the phenotype of patients with Gaucher disease in Japan differs from that in non-Japanese populations. Some patients with type 1 Gaucher disease in Japan have more severe and progressive disease compared to non-Japanese patients and the disease is characterized by an earlier onset of symptoms.

Velaglucerase alfa, a highly-purified form of the naturally occurring enzyme glucocerebrosidase, has been developed as an enzyme replacement therapy for Gaucher disease for the symptoms (anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone manifestation).

The primary objective of this study is to evaluate the safety of every other week dosing of velaglucerase alfa in Japanese patients (naive or previously treated with imiglucerase) 2 years of age and older with Gaucher disease.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient has a documented diagnosis of Gaucher disease
  • The patient is at least 2 years of age
  • Female patients of child bearing potential must agree to use a medically acceptable method of contraception at all times during the study
  • The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC)
  • The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator

Patients who are switched from imiglucerase ERT must meet the following additional criteria:

  • Received treatment with imiglucerase for a minimum of 12 consecutive months
  • Meet predefined limits for hemoglobin concentration and platelet counts

Patients naïve to treatment for Gaucher disease must meet the following additional criteria:

  • Not received treatment for Gaucher disease (investigational or approved products) within 12 months prior to study entry
  • Have Gaucher disease related anemia and at least one of the following: moderate splenomegaly or, Gaucher disease-related thrombocytopenia or Gaucher disease-related enlarged liver

Exclusion Criteria:

  • Treatment with any investigational drug or device within the 30 days prior to study entry (time of informed consent); such use during the study is not permitted
  • Positive for hepatitis B or hepatitis C.
  • Non-Gaucher disease related anemia
  • The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study
  • Significant comorbidity, as determined by the Investigator that might affect study data or confound the study results
  • The patient is unable to comply with the protocol or is unlikely to complete the study, as determined by the Investigator
  • The patient has experienced a severe (grade 3 or higher) infusion-related hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any ERT (approved or investigational)
  • Currently receiving red blood cell growth factor, (eg, erythropoietin) or chronic systemic corticosteroids in the last 6 months
  • Patient has had a splenectomy or the patient has an active, clinically significant spleen infarction within 12 months of screening
  • Patient has worsening bone necrosis within 12 months of screening
  • The patient is pregnant or lactating.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01614574

Locations
Japan
Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, Japan, 431-3192
The Jikei University School of Medicine
Minato-ku, Toyko, Japan, 105-8461
Osaka City University Hospital
Osaka, Japan, 545-0051
Sponsors and Collaborators
Shire Human Genetic Therapies, Inc.
Investigators
Study Director: Eric Crombez, M.D. Shire Human Genetic Therapies, Inc.
  More Information

No publications provided

Responsible Party: Shire Human Genetic Therapies, Inc.
ClinicalTrials.gov Identifier: NCT01614574     History of Changes
Other Study ID Numbers: HGT-GCB-087
Study First Received: June 6, 2012
Last Updated: May 31, 2013
Health Authority: United States: Food and Drug Administration
Japan: Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Gaucher Disease
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on April 17, 2014